Story perspectives

FDA to Cut Advisory Reviews, Sparking Transparency Concerns

9/13/2025

39 5

Summary

Story summary

The FDA plans to eliminate expert advisory committee reviews for drug applications, citing redundancy and workload issues.
Critics warn this decision may diminish public scrutiny and transparency in drug approvals.
The FDA is publishing complete response letters to enhance transparency, though former officials emphasize the need for advisory meetings.
The agency is targeting misleading marketing practices, issuing warnings to companies like Hims & Hers for unapproved compounded drugs.
These actions reflect a broader strategy to regulate pharmaceutical advertising and protect consumer safety.

1 of 1

Story summary

The FDA plans to eliminate expert advisory committee reviews for drug applications, citing redundancy and workload issues.
Critics warn this decision may diminish public scrutiny and transparency in drug approvals.
The FDA is publishing complete response letters to enhance transparency, though former officials emphasize the need for advisory meetings.
The agency is targeting misleading marketing practices, issuing warnings to companies like Hims & Hers for unapproved compounded drugs.
These actions reflect a broader strategy to regulate pharmaceutical advertising and protect consumer safety.